Approved TherapeuticAugust 5, 2026
Semaglutide
Ozempic
Type 2 diabetes · Chronic weight management
Tier 1Approved
SafetyKnown but Manageable Risks
- Sponsor
- Novo Nordisk
- Phase
- Approved
Loading Daily Peptide Guide…
Recent pipeline, trial and regulatory activity. Dates and status should be reconfirmed against primary sources.
Ozempic
Type 2 diabetes · Chronic weight management
Tymlos
Osteoporosis · High fracture risk
Linzess
Irritable bowel syndrome with constipation · Chronic idiopathic constipation
Egrifta
Excess abdominal fat in adults with HIV-associated lipodystrophy
BI 456906
Obesity · MASH
LY3841136
Obesity
Cibinetide
Small-fiber neuropathy · Inflammatory conditions
GHSR agonist programs
Cachexia research · Appetite-loss research
HN peptide
Neuroprotection research · Longevity claims
Examorelin
Growth hormone claims · Body-composition claims
Tβ4
Wound-healing research · Recovery claims
Mounjaro
Type 2 diabetes · Chronic weight management
Sandostatin
Acromegaly · Carcinoid syndrome
Trulance
Chronic idiopathic constipation · IBS-C
Lutathera
Gastroenteropancreatic neuroendocrine tumors · Theranostics
MariTide
Obesity · Type 2 diabetes
Experimental metabolic peptide
Obesity · Metabolic disease
BYM338
Body-composition research · Muscle-wasting research
GLP-1 multi-agonist class
Obesity · Weight management research
Epithalon
Longevity claims · Sleep claims
Pralmorelin
Growth hormone claims · Body-composition claims
ACTH(4-7)-PGP
Cognition claims · Neurologic research
Victoza
Type 2 diabetes · Chronic weight management
Somatuline Depot
Acromegaly · Neuroendocrine tumors
Prialt
Severe chronic pain